Skip to main content
INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
7.67
+1.15 (17.55%)
Jan 22, 2025, 4:00 PM EST - Market closed

INmune Bio Revenue

INmune Bio had revenue of $42.00K in the twelve months ending September 30, 2024, down -81.25% year-over-year. In the year 2023, INmune Bio had annual revenue of $155.00K, down -58.56%.

Revenue (ttm)
$42.00K
Revenue Growth
-81.25%
P/S Ratio
n/a
Revenue / Employee
$2,471
Employees
17
Market Cap
170.06M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023155.00K-219.00K-58.56%
Dec 31, 2022374.00K193.00K106.63%
Dec 31, 2021181.00K170.00K1,545.45%
Dec 31, 202011.00K--
Dec 31, 2019---
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 400.28B
Johnson & Johnson 87.70B
Merck & Co. 63.17B
AbbVie 55.53B
AstraZeneca 51.21B
Novartis AG 49.94B
Thermo Fisher Scientific 42.37B
Abbott Laboratories 41.22B
Revenue Rankings

INMB News

More News